Inhibition of Serine Metabolism Promotes Resistance to Cisplatin in Gastric Cancer.
DNA damage
PHGDH
cisplatin resistance
gastric cancer
serine metabolism
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
epublish
Résumé
Serine provides important precursors of protein, lipid, and nucleotide synthesis needed for tumor cell growth. Phosphoglycerate dehydrogenase (PHGDH), a key rate-limiting enzyme in the serine de novo synthesis pathway, is highly expressed in many tumor types (including gastric cancer) and negatively correlated with overall survival. Cisplatin is a chemotherapeutic drug commonly used in the treatment of gastric cancer. In this study, we mainly investigated the relationship between serine metabolism and resistance to cisplatin in gastric cancer cells, as well as the regulatory mechanism involved in this process. We determined the effect of different concentrations of serine or a PHGDH inhibitor combined with cisplatin or oxaliplatin on the viability and apoptosis of SGC7901, BGC823, and MGC803 cells via the Cell Counting Kit-8 and Hoechst 33258 staining, respectively. Western blotting was utilized to detect the relative protein expression. Furthermore, we investigated DNA damage through the micrococcal nuclease sensitivity assay detected using agarose gels. We found that reduced concentrations of serine or inhibition of PHGDH hindered the toxicity and pro-apoptotic effects of cisplatin on gastric cancer cells. Moreover, the addition of serine could reverse the sensitivity of gastric cancer cells to cisplatin. Moreover, we found that DNA damage was reduced by treatment with PHGDH inhibitor NCT-503 or CBR-5884. Inhibition of serine metabolism induced a decrease in H3K4 tri-methylation, which was reversed by JIB-04 (inhibitor of H3K4 demethylase). The tolerance of gastric cancer cells to cisplatin was relieved by JIB-04. Through micrococcal nuclease experiments, we further found that inhibiting the activity of PHGDH strengthened chromatin tightness. Inhibition of serine metabolism reduced H3K4 tri-methylation and increased the density of chromatin, which leads to decreased toxicity and pro-apoptotic effect of platinum chemotherapeutic drugs on gastric cancer cells.
Sections du résumé
BACKGROUND
BACKGROUND
Serine provides important precursors of protein, lipid, and nucleotide synthesis needed for tumor cell growth. Phosphoglycerate dehydrogenase (PHGDH), a key rate-limiting enzyme in the serine de novo synthesis pathway, is highly expressed in many tumor types (including gastric cancer) and negatively correlated with overall survival. Cisplatin is a chemotherapeutic drug commonly used in the treatment of gastric cancer. In this study, we mainly investigated the relationship between serine metabolism and resistance to cisplatin in gastric cancer cells, as well as the regulatory mechanism involved in this process.
MATERIALS AND METHODS
METHODS
We determined the effect of different concentrations of serine or a PHGDH inhibitor combined with cisplatin or oxaliplatin on the viability and apoptosis of SGC7901, BGC823, and MGC803 cells via the Cell Counting Kit-8 and Hoechst 33258 staining, respectively. Western blotting was utilized to detect the relative protein expression. Furthermore, we investigated DNA damage through the micrococcal nuclease sensitivity assay detected using agarose gels.
RESULTS
RESULTS
We found that reduced concentrations of serine or inhibition of PHGDH hindered the toxicity and pro-apoptotic effects of cisplatin on gastric cancer cells. Moreover, the addition of serine could reverse the sensitivity of gastric cancer cells to cisplatin. Moreover, we found that DNA damage was reduced by treatment with PHGDH inhibitor NCT-503 or CBR-5884. Inhibition of serine metabolism induced a decrease in H3K4 tri-methylation, which was reversed by JIB-04 (inhibitor of H3K4 demethylase). The tolerance of gastric cancer cells to cisplatin was relieved by JIB-04. Through micrococcal nuclease experiments, we further found that inhibiting the activity of PHGDH strengthened chromatin tightness.
CONCLUSION
CONCLUSIONS
Inhibition of serine metabolism reduced H3K4 tri-methylation and increased the density of chromatin, which leads to decreased toxicity and pro-apoptotic effect of platinum chemotherapeutic drugs on gastric cancer cells.
Identifiants
pubmed: 32581546
doi: 10.2147/OTT.S246430
pii: 246430
pmc: PMC7269635
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4833-4842Informations de copyright
© 2020 Zhao et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Cancer Res. 1970 Dec;30(12):2917-20
pubmed: 4321975
Int J Biol Sci. 2020 Mar 5;16(9):1495-1506
pubmed: 32226297
Cancer Biol Ther. 2015;16(4):541-8
pubmed: 25719555
Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19464-19473
pubmed: 31488723
Transl Oncol. 2016 Dec;9(6):592-599
pubmed: 27916294
Nat Cell Biol. 2011 Oct 03;13(10):1161-9
pubmed: 21968989
Nat Rev Cancer. 2013 Oct;13(10):714-26
pubmed: 24060863
Int J Clin Exp Med. 2015 Oct 15;8(10):17634-43
pubmed: 26770353
Theranostics. 2018 Feb 12;8(7):1808-1823
pubmed: 29556358
Nat Rev Mol Cell Biol. 2018 Sep;19(9):563-578
pubmed: 29930302
Essays Biochem. 2012;52:93-111
pubmed: 22708566
Bioorg Chem. 2019 Jun;87:16-22
pubmed: 30852233
Nat Rev Cancer. 2012 Oct;12(10):709-20
pubmed: 22952011
Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1778-83
pubmed: 26831078
Mol Oncol. 2015 Oct;9(8):1636-54
pubmed: 26026368
J Biol Chem. 2013 Jul 19;288(29):21376-88
pubmed: 23744078
Transl Oncol. 2016 Jun;9(3):191-6
pubmed: 27267836
J Cell Biol. 2016 Aug 1;214(3):249-57
pubmed: 27458133
Front Oncol. 2018 Feb 05;8:15
pubmed: 29459886
Curr Biol. 2000 Jul 27-Aug 10;10(15):886-95
pubmed: 10959836
Int J Mol Sci. 2019 Jul 31;20(15):
pubmed: 31370155
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Molecules. 2019 May 04;24(9):
pubmed: 31060229
Cancer Res. 1992 Mar 15;52(6):1580-6
pubmed: 1540967
Onco Targets Ther. 2016 Sep 07;9:5553-60
pubmed: 27660473
Nat Struct Mol Biol. 2010 Sep;17(9):1144-51
pubmed: 20802485
Zhonghua Zhong Liu Za Zhi. 2018 Jan 23;40(1):5-13
pubmed: 29365411
Gastric Cancer. 2016 Jul;19(3):986-93
pubmed: 26407875
Cell. 2006 Dec 29;127(7):1361-73
pubmed: 17190600
Cancer Res. 1955 Dec;15(11):715-8
pubmed: 13270262
Food Funct. 2019 Jun 19;10(6):3386-3395
pubmed: 31112178
Gene. 2018 Feb 5;642:43-50
pubmed: 29128633
Nat Commun. 2019 Jan 18;10(1):309
pubmed: 30659176
BMC Cancer. 2019 Jul 22;19(1):723
pubmed: 31331318
Oncology. 2015;89(6):351-9
pubmed: 26439504
Nat Commun. 2019 Oct 15;10(1):4681
pubmed: 31615983
Oncotarget. 2013 Dec;4(12):2502-11
pubmed: 24318446
Nat Genet. 2011 Jul 31;43(9):869-74
pubmed: 21804546
Cancer Res. 2017 Nov 15;77(22):6321-6329
pubmed: 28951458
Cancer Chemother Pharmacol. 2016 Sep;78(3):655-9
pubmed: 27473325
Cancer Discov. 2020 Feb;10(2):306-325
pubmed: 31776131
J Biol Chem. 2012 Jun 8;287(24):19786-91
pubmed: 22566694
PLoS One. 2017 May 9;12(5):e0177372
pubmed: 28486547
Cancer Res. 2015 Jun 1;75(11):2133-8
pubmed: 25931285
Mol Cancer Ther. 2017 Aug;16(8):1596-1609
pubmed: 28500236
Pharmacol Res. 2016 Apr;106:27-36
pubmed: 26804248
PLoS Comput Biol. 2007 Aug;3(8):e155
pubmed: 17676951
Nature. 2004 Nov 18;432(7015):406-11
pubmed: 15525939
Cell Cycle. 2011 Jan 15;10(2):261-7
pubmed: 21212734
Cancer Metab. 2017 Aug 29;5:7
pubmed: 28855983
Int J Biol Sci. 2018 Jun 22;14(9):1122-1132
pubmed: 29989047
Cancer Res. 2019 Jan 1;79(1):86-98
pubmed: 30459150
Mol Genet Metab. 2010 Mar;99(3):256-62
pubmed: 19963421
Proc Natl Acad Sci U S A. 2018 May 22;115(21):E4777-E4785
pubmed: 29735688